| Excerpt | Relevance | Reference |
|---|
| "To determine whether the addition of aminoglutethimide to tamoxifen is able to improve the outcome in postmenopausal patients with hormone receptor-positive, early-stage breast cancer." | 9.10 | Randomized trial of tamoxifen versus tamoxifen plus aminoglutethimide as adjuvant treatment in postmenopausal breast cancer patients with hormone receptor-positive disease: Austrian breast and colorectal cancer study group trial 6. ( Fridrik, M; Gnant, M; Haider, K; Hausmaninger, H; Jakesz, R; Kubista, E; Kwasny, W; Menzel, C; Mlineritsch, B; Samonigg, H; Schmid, M; Seifert, M; Steger, G; Steindorfer, P; Stierer, M; Taucher, S; Tausch, C; Wette, V, 2003) |
| "The efficacy of combined endocrine therapy with tamoxifen (TAM), aminoglutethimide (AG), and hydrocortisone (H) or tamoxifen and fluoxymesterone (FLU) was evaluated against treatment with tamoxifen alone in 311 patients above 65 years of age with a first recurrence of a metastatic breast cancer." | 9.09 | Combined endocrine treatment of elderly postmenopausal patients with metastatic breast cancer. A randomized trial of tamoxifen vs. tamoxifen + aminoglutethimide and hydrocortisone and tamoxifen + fluoxymesterone in women above 65 years of age. ( Andersen, J; Andersson, M; Bastholt, L; Christensen, IJ; Dombernowsky, P; Kamby, C; Mouridsen, HT; Munkholm, P; Møller, KA; Rose, C, 2000) |
| "In a European multicentre phase II study, 80 postmenopausal patients (pts) with advanced breast cancer progressing on aminoglutethimide (AG) at daily doses of > or = 500 mg were enrolled." | 9.08 | Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on aminoglutethimide: a phase II multicentre multinational study. Exemestane Study Group. ( Bonneterre, J; di Salle, E; Lanzalone, S; Murray, R; Paridaens, R; Piscitelli, G; Roché, H; Serin, D; Thürlimann, B; Zurlo, MG, 1997) |
| "The study compares letrozole and aminoglutethimide (AG), a standard therapy for postmenopausal women with advanced breast cancer, previously treated with antioestrogens." | 9.08 | Letrozole, a new oral aromatase inhibitor: randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Letrozole International Trial Group (AR/BC3). ( Bodrogi, I; Bonaventura, A; Buzzi, F; Campos, D; Chaudri, HA; Friederich, P; Gershanovich, M; Jeffrey, M; Lassus, M; Ludwig, H; Lurie, H; O'Higgins, N; Reichardt, P; Romieu, G, 1998) |
| "To determine whether the addition of aminoglutethimide to tamoxifen is able to improve the outcome in postmenopausal patients with hormone receptor-positive, early-stage breast cancer." | 5.10 | Randomized trial of tamoxifen versus tamoxifen plus aminoglutethimide as adjuvant treatment in postmenopausal breast cancer patients with hormone receptor-positive disease: Austrian breast and colorectal cancer study group trial 6. ( Fridrik, M; Gnant, M; Haider, K; Hausmaninger, H; Jakesz, R; Kubista, E; Kwasny, W; Menzel, C; Mlineritsch, B; Samonigg, H; Schmid, M; Seifert, M; Steger, G; Steindorfer, P; Stierer, M; Taucher, S; Tausch, C; Wette, V, 2003) |
| "The efficacy of combined endocrine therapy with tamoxifen (TAM), aminoglutethimide (AG), and hydrocortisone (H) or tamoxifen and fluoxymesterone (FLU) was evaluated against treatment with tamoxifen alone in 311 patients above 65 years of age with a first recurrence of a metastatic breast cancer." | 5.09 | Combined endocrine treatment of elderly postmenopausal patients with metastatic breast cancer. A randomized trial of tamoxifen vs. tamoxifen + aminoglutethimide and hydrocortisone and tamoxifen + fluoxymesterone in women above 65 years of age. ( Andersen, J; Andersson, M; Bastholt, L; Christensen, IJ; Dombernowsky, P; Kamby, C; Mouridsen, HT; Munkholm, P; Møller, KA; Rose, C, 2000) |
| "In a European multicentre phase II study, 80 postmenopausal patients (pts) with advanced breast cancer progressing on aminoglutethimide (AG) at daily doses of > or = 500 mg were enrolled." | 5.08 | Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on aminoglutethimide: a phase II multicentre multinational study. Exemestane Study Group. ( Bonneterre, J; di Salle, E; Lanzalone, S; Murray, R; Paridaens, R; Piscitelli, G; Roché, H; Serin, D; Thürlimann, B; Zurlo, MG, 1997) |
| "The study compares letrozole and aminoglutethimide (AG), a standard therapy for postmenopausal women with advanced breast cancer, previously treated with antioestrogens." | 5.08 | Letrozole, a new oral aromatase inhibitor: randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Letrozole International Trial Group (AR/BC3). ( Bodrogi, I; Bonaventura, A; Buzzi, F; Campos, D; Chaudri, HA; Friederich, P; Gershanovich, M; Jeffrey, M; Lassus, M; Ludwig, H; Lurie, H; O'Higgins, N; Reichardt, P; Romieu, G, 1998) |